Tenaya Therapeutics (TNYA) Return on Capital Employed (2021 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Return on Capital Employed of 69.12% for Q1 2026, up 2403.0% year-over-year from 2.76% in Q1 2025, and up 18.15% quarter-over-quarter from 84.45% in Q4 2025.
Tenaya Therapeutics (TNYA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Tenaya Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 69.12% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2403.0% year-over-year to 69.12%; the TTM figure through Mar 2026 stood at 69.12% (up 2403.0% YoY), while the FY2025 annual figure was 79.1%, up 1061.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 69.12%, up from 84.45% in the prior quarter.
- The five-year high for Return on Capital Employed was 32.59% in Q1 2022, with the low at 101.45% in Q4 2024.
- The 5-year median for Return on Capital Employed is 80.69% (2024), against an average of 72.73%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed tumbled 3083 bps in 2022, then surged 2403 bps in 2026.
- Tenaya Therapeutics' Return on Capital Employed stood at 55.01% in 2022, then plunged by 50 bps to 82.4% in 2023, then declined by 23 bps to 101.45% in 2024, then grew by 17 bps to 84.45% in 2025, then climbed by 18 bps to 69.12% in 2026.
- Business Quant data shows TNYA's Return on Capital Employed at 69.12% in Q1 2026, 84.45% in Q4 2025, and 96.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | -111.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -111.10% |
| Mar 31, 2026 | -69.12% |
| Dec 31, 2025 | -84.45% |
| Sep 30, 2025 | -96.86% |
| Jun 30, 2025 | -85.54% |
| Mar 31, 2025 | -93.15% |
| Dec 31, 2024 | -101.45% |
| Sep 30, 2024 | -90.45% |
| Jun 30, 2024 | -80.69% |
| Mar 31, 2024 | -82.77% |
| Dec 31, 2023 | -82.40% |
| Sep 30, 2023 | -71.55% |
| Jun 30, 2023 | -63.49% |
| Mar 31, 2023 | -52.79% |
| Dec 31, 2022 | -55.01% |
| Sep 30, 2022 | -52.48% |
| Jun 30, 2022 | -41.70% |
| Mar 31, 2022 | -32.59% |
| Dec 31, 2021 | -24.17% |
| Sep 30, 2021 | -24.70% |